Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

S. Herbst, Roy; B. Garon, Edward; Kim, Dong‐Wan; Chul Cho, Byoung; Luis Perez‐Gracia, José; Han, Ji‐Youn; Dubos Arvis, Catherine; Majem, Margarita; Förster, Martin; Monnet, I.; Novello, Silvia; Szalai, Zsuzsanna; A. Gubens, Matthew; Su, Wu‐Chou; Luca Ceresoli, Giovanni; Samkari, Ayman; Jensen, Erin; M. Lubiniecki, Gregory; Baas, Paul

doi:10.1200/jco.19.02446

Public

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Published in Journal of Clinical Oncology • Feb 20, 2020

Authors:

Roy S. Herbst

Edward B. Garon

Dong‐Wan Kim

Abstract

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report KEYNOTE-010 long-t...

Subject

Pembrolizumab

Medicine

Docetaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!